Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

Modification of an Established Pediatric Asthma Pathway Improves Evidence-Based, Efficient Care.

Rutman L, Atkins RC, Migita R, Foti J, Spencer S, Lion KC, Wright DR, Leu MG, Zhou C, Mangione-Smith R.

Pediatrics. 2016 Dec;138(6). pii: e20161248.

PMID:
27940683
2.

A Framework for Evaluating Value of New Clinical Recommendations.

Leu MG, Austin E, Foti JL, Hrachovec J, Popalisky J, Spencer SM, OHare P, Migita DS.

Hosp Pediatr. 2016 Oct;6(10):578-586. No abstract available.

PMID:
27677496
3.

Resource utilization after implementing a hospital-wide standardized feeding tube placement pathway.

Richards MK, Li CI, Foti JL, Leu MG, Wahbeh GT, Shaw D, Libby AK, Melzer L, Goldin AB.

J Pediatr Surg. 2016 Oct;51(10):1674-9. doi: 10.1016/j.jpedsurg.2016.05.012.

PMID:
27306489
4.

Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.

O'Brien KL, Chandran A, Weatherholtz R, Jafri HS, Griffin MP, Bellamy T, Millar EV, Jensen KM, Harris BS, Reid R, Moulton LH, Losonsky GA, Karron RA, Santosham M; Respiratory Syncytial Virus (RSV) Prevention study group..

Lancet Infect Dis. 2015 Dec;15(12):1398-408. doi: 10.1016/S1473-3099(15)00247-9.

PMID:
26511956
5.

A chemical genetics analysis of the roles of bypass polymerase DinB and DNA repair protein AlkB in processing N2-alkylguanine lesions in vivo.

Shrivastav N, Fedeles BI, Li D, Delaney JC, Frick LE, Foti JJ, Walker GC, Essigmann JM.

PLoS One. 2014 Apr 14;9(4):e94716. doi: 10.1371/journal.pone.0094716.

6.

Oxidation of the guanine nucleotide pool underlies cell death by bactericidal antibiotics.

Foti JJ, Devadoss B, Winkler JA, Collins JJ, Walker GC.

Science. 2012 Apr 20;336(6079):315-9. doi: 10.1126/science.1219192.

7.

Efficient extension of slipped DNA intermediates by DinB is required to escape primer template realignment by DnaQ.

Foti JJ, Walker GC.

J Bacteriol. 2011 May;193(10):2637-41. doi: 10.1128/JB.00005-11.

8.

Medication adherence in children and adolescents with HIV infection: associations with behavioral impairment.

Malee K, Williams P, Montepiedra G, McCabe M, Nichols S, Sirois PA, Storm D, Farley J, Kammerer B; PACTG 219C Team..

AIDS Patient Care STDS. 2011 Mar;25(3):191-200. doi: 10.1089/apc.2010.0181.

9.

UmuD(2) inhibits a non-covalent step during DinB-mediated template slippage on homopolymeric nucleotide runs.

Foti JJ, Delucia AM, Joyce CM, Walker GC.

J Biol Chem. 2010 Jul 23;285(30):23086-95. doi: 10.1074/jbc.M110.115774.

10.

SnapShot: DNA polymerases II mammals.

Foti JJ, Walker GC.

Cell. 2010 Apr 16;141(2):370-370.e1. doi: 10.1016/j.cell.2010.04.005. No abstract available.

11.

SnapShot: DNA polymerases I prokaryotes.

Foti JJ, Walker GC.

Cell. 2010 Apr 2;141(1):192-192.e1. doi: 10.1016/j.cell.2010.03.024. No abstract available.

12.

Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants.

Williams PL, Marino M, Malee K, Brogly S, Hughes MD, Mofenson LM; PACTG 219C Team..

Pediatrics. 2010 Feb;125(2):e250-60. doi: 10.1542/peds.2009-1112.

13.

The use of second-generation antipsychotics and the changes in physical growth in children and adolescents with perinatally acquired HIV.

Kapetanovic S, Aaron L, Montepiedra G, Sirois PA, Oleske JM, Malee K, Pearson DA, Nichols SL, Garvie PA, Farley J, Nozyce ML, Mintz M, Williams PL; Pediatric AIDS Clinical Trials..

AIDS Patient Care STDS. 2009 Nov;23(11):939-47. doi: 10.1089/apc.2009.0121.

14.

Impact of medications prescribed for treatment of attention-deficit hyperactivity disorder on physical growth in children and adolescents with HIV.

Sirois PA, Montepiedra G, Kapetanovic S, Williams PL, Pearson DA, Malee K, Garvie PA, Kammerer BL, Nichols SL, Nozyce ML, Mintz M, Mitchell WG, Oleske JM; IMPAACT/PACTG 219C Team..

J Dev Behav Pediatr. 2009 Oct;30(5):403-12.

15.

Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents.

Patel K, Ming X, Williams PL, Robertson KR, Oleske JM, Seage GR 3rd; International Maternal Pediatric Adolescent AIDS Clinical Trials 219/219C Study Team..

AIDS. 2009 Sep 10;23(14):1893-901. doi: 10.1097/QAD.0b013e32832dc041.

16.

Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children.

Van Dyke RB, Wang L, Williams PL; Pediatric AIDS Clinical Trials Group 219C Team..

J Infect Dis. 2008 Dec 1;198(11):1599-608. doi: 10.1086/593022.

17.

The SOS Regulatory Network.

Simmons LA, Foti JJ, Cohen SE, Walker GC.

EcoSal Plus. 2008 Sep;3(1). doi: 10.1128/ecosalplus.5.4.3.

PMID:
26443738
18.

The SOS Regulatory Network.

Simmons LA, Foti JJ, Cohen SE, Walker GC.

EcoSal Plus. 2008 Jul 25;2008. doi: 10.1128/ecosalplus.5.4.3.

19.

The role of cognitive functioning in medication adherence of children and adolescents with HIV infection.

Malee K, Williams PL, Montepiedra G, Nichols S, Sirois PA, Storm D, Farley J, Kammerer B; PACTG 219C Team..

J Pediatr Psychol. 2009 Mar;34(2):164-75. doi: 10.1093/jpepsy/jsn068.

20.

Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting.

Patel K, HernĂ¡n MA, Williams PL, Seeger JD, McIntosh K, Dyke RB, Seage GR 3rd; Pediatric AIDS Clinical Trials Group 219/219C Study Team..

Clin Infect Dis. 2008 Jun 1;46(11):1751-60. doi: 10.1086/587900.

Items per page

Supplemental Content

Loading ...
Support Center